 Brett Stevens
Concepts (229)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 22 | 2023 | 532 | 3.990 |
Why?
| | Myelodysplastic Syndromes | 4 | 2020 | 119 | 1.990 |
Why?
| | Neoplastic Stem Cells | 13 | 2023 | 336 | 1.790 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 10 | 2023 | 1390 | 1.350 |
Why?
| | Proto-Oncogene Proteins c-cbl | 3 | 2014 | 12 | 1.120 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 10 | 2023 | 165 | 1.100 |
Why?
| | Interleukin-3 Receptor alpha Subunit | 2 | 2019 | 16 | 0.870 |
Why?
| | Azacitidine | 7 | 2023 | 119 | 0.860 |
Why?
| | Flow Cytometry | 3 | 2020 | 1085 | 0.820 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2020 | 671 | 0.690 |
Why?
| | Hematopoietic Stem Cells | 2 | 2021 | 359 | 0.690 |
Why?
| | Reactive Oxygen Species | 2 | 2020 | 576 | 0.680 |
Why?
| | Salvage Therapy | 1 | 2019 | 130 | 0.640 |
Why?
| | Proto-Oncogene Proteins c-fyn | 2 | 2014 | 12 | 0.630 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2018 | 317 | 0.630 |
Why?
| | Sulfonamides | 8 | 2022 | 445 | 0.610 |
Why?
| | Immunotherapy, Adoptive | 1 | 2019 | 191 | 0.600 |
Why?
| | Neoplasms, Plasma Cell | 1 | 2015 | 6 | 0.550 |
Why?
| | Mice, Inbred NOD | 7 | 2020 | 574 | 0.550 |
Why?
| | Leukocytosis | 1 | 2015 | 34 | 0.550 |
Why?
| | Clonal Evolution | 1 | 2015 | 26 | 0.530 |
Why?
| | Mice, SCID | 5 | 2020 | 333 | 0.520 |
Why?
| | Computational Biology | 1 | 2019 | 588 | 0.510 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2020 | 900 | 0.500 |
Why?
| | Rho Guanine Nucleotide Exchange Factors | 1 | 2014 | 19 | 0.500 |
Why?
| | Leukemia | 3 | 2020 | 208 | 0.450 |
Why?
| | Cell Proliferation | 4 | 2021 | 2275 | 0.450 |
Why?
| | Oxidative Phosphorylation | 5 | 2022 | 156 | 0.440 |
Why?
| | Glioblastoma | 1 | 2014 | 262 | 0.400 |
Why?
| | Carrier Proteins | 1 | 2015 | 726 | 0.400 |
Why?
| | Nuclear Proteins | 1 | 2015 | 597 | 0.390 |
Why?
| | Neutrophils | 1 | 2015 | 1233 | 0.360 |
Why?
| | Mutation | 2 | 2020 | 3457 | 0.350 |
Why?
| | Multiple Myeloma | 2 | 2020 | 100 | 0.340 |
Why?
| | Cell Self Renewal | 2 | 2019 | 51 | 0.330 |
Why?
| | Fatty Acids | 3 | 2020 | 407 | 0.320 |
Why?
| | Stem Cells | 3 | 2020 | 559 | 0.310 |
Why?
| | Humans | 36 | 2023 | 118974 | 0.290 |
Why?
| | Amino Acids | 2 | 2020 | 465 | 0.270 |
Why?
| | Mice | 15 | 2021 | 15520 | 0.270 |
Why?
| | Animals | 18 | 2021 | 33381 | 0.250 |
Why?
| | Proto-Oncogene Proteins c-myc | 2 | 2022 | 115 | 0.240 |
Why?
| | Interferon Regulatory Factors | 2 | 2020 | 31 | 0.240 |
Why?
| | Tumor Cells, Cultured | 4 | 2022 | 874 | 0.230 |
Why?
| | Finland | 1 | 2023 | 71 | 0.230 |
Why?
| | Uncertainty | 1 | 2023 | 101 | 0.220 |
Why?
| | Electron Transport Complex II | 2 | 2019 | 24 | 0.220 |
Why?
| | Amino Acid Transport System ASC | 1 | 2022 | 9 | 0.210 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2022 | 41 | 0.210 |
Why?
| | Trans-Activators | 2 | 2021 | 373 | 0.190 |
Why?
| | Nuclear Receptor Co-Repressor 2 | 1 | 2020 | 14 | 0.190 |
Why?
| | Bone Marrow Diseases | 1 | 2020 | 18 | 0.190 |
Why?
| | Protein Synthesis Inhibitors | 1 | 2020 | 47 | 0.190 |
Why?
| | Neoplasms | 1 | 2014 | 2179 | 0.190 |
Why?
| | Proto-Oncogene Proteins c-ets | 1 | 2020 | 51 | 0.190 |
Why?
| | Oxidation-Reduction | 4 | 2019 | 940 | 0.190 |
Why?
| | RNA Splicing Factors | 1 | 2020 | 50 | 0.190 |
Why?
| | Lipase | 1 | 2020 | 70 | 0.190 |
Why?
| | STAT3 Transcription Factor | 1 | 2022 | 189 | 0.180 |
Why?
| | Decision Support Systems, Clinical | 1 | 2022 | 178 | 0.180 |
Why?
| | Germ-Line Mutation | 1 | 2020 | 134 | 0.180 |
Why?
| | Signal Transduction | 5 | 2022 | 4709 | 0.180 |
Why?
| | Leukopoiesis | 1 | 2019 | 10 | 0.170 |
Why?
| | Lentivirus | 1 | 2019 | 52 | 0.170 |
Why?
| | Myeloid Progenitor Cells | 1 | 2019 | 16 | 0.170 |
Why?
| | NADPH Oxidase 2 | 1 | 2019 | 42 | 0.170 |
Why?
| | Cytarabine | 1 | 2019 | 53 | 0.170 |
Why?
| | Mitochondrial Proteins | 2 | 2018 | 226 | 0.170 |
Why?
| | Histone Deacetylases | 1 | 2020 | 198 | 0.170 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2019 | 83 | 0.170 |
Why?
| | Homeostasis | 2 | 2021 | 594 | 0.170 |
Why?
| | Thrombocytopenia | 1 | 2020 | 185 | 0.160 |
Why?
| | Phosphoproteins | 1 | 2020 | 308 | 0.160 |
Why?
| | Bone Marrow | 2 | 2020 | 255 | 0.160 |
Why?
| | Protein Biosynthesis | 1 | 2020 | 397 | 0.160 |
Why?
| | Cation Transport Proteins | 1 | 2019 | 99 | 0.160 |
Why?
| | Cysteine | 1 | 2019 | 184 | 0.160 |
Why?
| | Cell Survival | 3 | 2022 | 1047 | 0.160 |
Why?
| | RNA Interference | 3 | 2014 | 460 | 0.160 |
Why?
| | Survival Rate | 2 | 2019 | 1720 | 0.160 |
Why?
| | Stress, Physiological | 1 | 2021 | 415 | 0.160 |
Why?
| | Aged, 80 and over | 5 | 2021 | 6561 | 0.160 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2016 | 93 | 0.160 |
Why?
| | Arthritis, Experimental | 1 | 2019 | 133 | 0.150 |
Why?
| | Proto-Oncogene Proteins | 1 | 2021 | 618 | 0.150 |
Why?
| | Repressor Proteins | 1 | 2020 | 377 | 0.150 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2018 | 178 | 0.150 |
Why?
| | Tumor Burden | 2 | 2016 | 274 | 0.150 |
Why?
| | Transplantation, Heterologous | 2 | 2014 | 194 | 0.150 |
Why?
| | Aged | 7 | 2021 | 19657 | 0.150 |
Why?
| | Female | 14 | 2021 | 61565 | 0.140 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2016 | 49 | 0.140 |
Why?
| | Neoplasm Proteins | 2 | 2016 | 401 | 0.140 |
Why?
| | Cells, Cultured | 3 | 2019 | 4077 | 0.140 |
Why?
| | Male | 10 | 2021 | 57801 | 0.140 |
Why?
| | HEK293 Cells | 2 | 2019 | 625 | 0.140 |
Why?
| | Oncogene Proteins | 1 | 2016 | 52 | 0.140 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2016 | 83 | 0.140 |
Why?
| | Cell Line, Tumor | 4 | 2018 | 2851 | 0.140 |
Why?
| | Autoimmune Diseases | 1 | 2019 | 398 | 0.140 |
Why?
| | Methyltransferases | 1 | 2016 | 61 | 0.130 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2016 | 64 | 0.130 |
Why?
| | Biomarkers, Tumor | 2 | 2019 | 1059 | 0.130 |
Why?
| | Gene Expression | 1 | 2020 | 1489 | 0.130 |
Why?
| | Chromosome Aberrations | 1 | 2015 | 136 | 0.130 |
Why?
| | Oligomycins | 1 | 2014 | 8 | 0.130 |
Why?
| | Cytokines | 3 | 2020 | 1900 | 0.130 |
Why?
| | Mitochondrial Proton-Translocating ATPases | 1 | 2014 | 18 | 0.130 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2016 | 99 | 0.130 |
Why?
| | fms-Like Tyrosine Kinase 3 | 1 | 2014 | 42 | 0.130 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2015 | 310 | 0.120 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 381 | 0.120 |
Why?
| | Carmustine | 1 | 2014 | 47 | 0.120 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2014 | 69 | 0.120 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 1868 | 0.120 |
Why?
| | Dacarbazine | 1 | 2014 | 102 | 0.120 |
Why?
| | Spheroids, Cellular | 1 | 2014 | 56 | 0.120 |
Why?
| | Tumor Suppressor Proteins | 1 | 2016 | 289 | 0.120 |
Why?
| | cdc42 GTP-Binding Protein | 1 | 2013 | 25 | 0.110 |
Why?
| | Follow-Up Studies | 2 | 2019 | 4596 | 0.110 |
Why?
| | Glucose | 1 | 2018 | 953 | 0.110 |
Why?
| | Fusion Proteins, bcr-abl | 2 | 2014 | 61 | 0.110 |
Why?
| | Protein Kinase Inhibitors | 2 | 2018 | 811 | 0.110 |
Why?
| | Retrospective Studies | 3 | 2021 | 12978 | 0.110 |
Why?
| | Inflammation | 2 | 2021 | 2566 | 0.110 |
Why?
| | Adaptation, Physiological | 1 | 2016 | 502 | 0.110 |
Why?
| | Tamoxifen | 1 | 2013 | 198 | 0.110 |
Why?
| | Liver | 1 | 2020 | 1816 | 0.110 |
Why?
| | Middle Aged | 5 | 2021 | 27617 | 0.110 |
Why?
| | Mice, Inbred C57BL | 5 | 2021 | 4908 | 0.110 |
Why?
| | Adipose Tissue | 1 | 2016 | 606 | 0.110 |
Why?
| | Membrane Proteins | 1 | 2018 | 1055 | 0.100 |
Why?
| | Biopsy | 1 | 2015 | 1079 | 0.100 |
Why?
| | Neoplasm, Residual | 2 | 2023 | 103 | 0.100 |
Why?
| | Blotting, Western | 1 | 2014 | 1194 | 0.100 |
Why?
| | Arthritis, Rheumatoid | 1 | 2019 | 989 | 0.100 |
Why?
| | Insulin Resistance | 1 | 2018 | 1180 | 0.090 |
Why?
| | Young Adult | 3 | 2021 | 10793 | 0.090 |
Why?
| | Succinate Dehydrogenase | 2 | 2019 | 44 | 0.090 |
Why?
| | Antineoplastic Agents | 2 | 2018 | 1974 | 0.080 |
Why?
| | Lymphoid Progenitor Cells | 1 | 2008 | 11 | 0.080 |
Why?
| | Energy Metabolism | 3 | 2019 | 767 | 0.080 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2008 | 58 | 0.080 |
Why?
| | Protein Binding | 1 | 2014 | 1975 | 0.080 |
Why?
| | Fresh Water | 1 | 2008 | 48 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2018 | 226 | 0.080 |
Why?
| | Disease Models, Animal | 4 | 2020 | 3730 | 0.070 |
Why?
| | Mice, Knockout | 3 | 2016 | 2680 | 0.060 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2008 | 267 | 0.060 |
Why?
| | Biodiversity | 1 | 2008 | 378 | 0.060 |
Why?
| | Antigens, CD34 | 1 | 2023 | 98 | 0.060 |
Why?
| | Adult | 3 | 2021 | 31512 | 0.060 |
Why?
| | Disease Progression | 2 | 2023 | 2490 | 0.060 |
Why?
| | Induction Chemotherapy | 1 | 2021 | 59 | 0.050 |
Why?
| | RNA, Small Interfering | 2 | 2014 | 564 | 0.050 |
Why?
| | Bacteria | 1 | 2008 | 757 | 0.050 |
Why?
| | Breast Neoplasms | 1 | 2013 | 1965 | 0.050 |
Why?
| | Prognosis | 2 | 2019 | 3443 | 0.050 |
Why?
| | Megakaryocytes | 1 | 2020 | 30 | 0.050 |
Why?
| | Spliceosomes | 1 | 2020 | 38 | 0.050 |
Why?
| | Adolescent | 1 | 2019 | 18480 | 0.050 |
Why?
| | Proteasome Inhibitors | 1 | 2020 | 44 | 0.050 |
Why?
| | Niacinamide | 1 | 2020 | 70 | 0.050 |
Why?
| | Primary Cell Culture | 1 | 2020 | 155 | 0.050 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2020 | 189 | 0.050 |
Why?
| | Drug Synergism | 1 | 2020 | 339 | 0.050 |
Why?
| | Cytogenetic Analysis | 1 | 2019 | 28 | 0.040 |
Why?
| | RNA Splicing | 1 | 2020 | 243 | 0.040 |
Why?
| | Tricarboxylic Acids | 1 | 2018 | 11 | 0.040 |
Why?
| | Remission Induction | 1 | 2019 | 247 | 0.040 |
Why?
| | Ketoglutaric Acids | 1 | 2018 | 16 | 0.040 |
Why?
| | Protein Transport | 1 | 2020 | 412 | 0.040 |
Why?
| | Machine Learning | 1 | 2022 | 331 | 0.040 |
Why?
| | Mice, Transgenic | 2 | 2018 | 2025 | 0.040 |
Why?
| | Cell Cycle | 1 | 2021 | 550 | 0.040 |
Why?
| | Cohort Studies | 2 | 2020 | 5116 | 0.040 |
Why?
| | Forkhead Transcription Factors | 1 | 2019 | 182 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2020 | 740 | 0.040 |
Why?
| | Biological Transport | 1 | 2018 | 382 | 0.040 |
Why?
| | Glutathione | 1 | 2019 | 324 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2020 | 502 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2020 | 454 | 0.040 |
Why?
| | Glycolysis | 1 | 2018 | 224 | 0.040 |
Why?
| | Apoptosis | 2 | 2018 | 2484 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2022 | 9342 | 0.040 |
Why?
| | Genetic Testing | 1 | 2019 | 389 | 0.040 |
Why?
| | Adenosine Triphosphate | 1 | 2019 | 439 | 0.040 |
Why?
| | Diet, High-Fat | 1 | 2018 | 247 | 0.040 |
Why?
| | NADP | 1 | 2016 | 50 | 0.040 |
Why?
| | Blast Crisis | 1 | 2016 | 19 | 0.040 |
Why?
| | Gonads | 1 | 2016 | 29 | 0.040 |
Why?
| | Deoxyglucose | 1 | 2016 | 46 | 0.040 |
Why?
| | CD36 Antigens | 1 | 2016 | 42 | 0.040 |
Why?
| | Cytoprotection | 1 | 2016 | 55 | 0.040 |
Why?
| | Myeloid Ecotropic Viral Integration Site 1 Protein | 1 | 2016 | 12 | 0.040 |
Why?
| | Sesquiterpenes | 1 | 2016 | 51 | 0.040 |
Why?
| | Lipolysis | 1 | 2016 | 42 | 0.040 |
Why?
| | Neoplasm Transplantation | 1 | 2016 | 245 | 0.030 |
Why?
| | Metabolome | 1 | 2018 | 296 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2016 | 278 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2018 | 477 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2021 | 745 | 0.030 |
Why?
| | Dihydrolipoyllysine-Residue Acetyltransferase | 1 | 2014 | 6 | 0.030 |
Why?
| | Ketone Oxidoreductases | 1 | 2014 | 7 | 0.030 |
Why?
| | Sirolimus | 1 | 2016 | 195 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2014 | 56 | 0.030 |
Why?
| | Imatinib Mesylate | 1 | 2014 | 64 | 0.030 |
Why?
| | Superoxides | 1 | 2014 | 221 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2021 | 1753 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1284 | 0.030 |
Why?
| | Recurrence | 1 | 2016 | 975 | 0.030 |
Why?
| | Up-Regulation | 1 | 2016 | 872 | 0.030 |
Why?
| | Homeodomain Proteins | 1 | 2016 | 468 | 0.030 |
Why?
| | Estrogen Receptor alpha | 1 | 2013 | 126 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2020 | 2275 | 0.030 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2014 | 407 | 0.020 |
Why?
| | Mitochondria | 1 | 2014 | 786 | 0.020 |
Why?
| | Biomarkers | 1 | 2019 | 3588 | 0.020 |
Why?
| | Insulin | 1 | 2018 | 2162 | 0.020 |
Why?
| | New York | 1 | 2008 | 118 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2008 | 180 | 0.020 |
Why?
| | Geography | 1 | 2008 | 190 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2008 | 536 | 0.020 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2008 | 514 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2008 | 755 | 0.020 |
Why?
| | Prospective Studies | 1 | 2016 | 6471 | 0.020 |
Why?
| | Phylogeny | 1 | 2008 | 816 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2008 | 2871 | 0.010 |
Why?
| | Child | 1 | 2020 | 19129 | 0.010 |
Why?
|
|
Stevens's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|